-
EP4161956
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4161956
| EP4161956 - IL-2 SEQUENCES AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 10.03.2023 Database last updated on 27.07.2024 | |
| Former | The international publication has been made Status updated on 10.12.2021 | ||
| Former | unknown Status updated on 11.06.2021 | Most recent event Tooltip | 02.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Ascendis Pharma Oncology Division A/S Tuborg Boulevard 12 2900 Hellerup / DK | [2023/15] | Inventor(s) | 01 /
GUNNARSSON, Nina 2900 Hellerup / DK | 02 /
MALECKIS, Matiss 2900 Hellerup / DK | 03 /
ROSEN, David B Palo Alto, California 94304 / US | [2023/15] | Representative(s) | Büchel, Edwin Patentanwälte Isenbruck Bösl Hörschler PartG mbB Eastsite One Seckenheimer Landstraße 4 68163 Mannheim / DE | [2023/15] | Application number, filing date | 21729562.5 | 02.06.2021 | [2023/15] | WO2021EP64781 | Priority number, date | EP20200177974 | 03.06.2020 Original published format: EP 20177974 | EP20200202299 | 16.10.2020 Original published format: EP 20202299 | US202063116102P | 19.11.2020 Original published format: US 202063116102 P | EP20200216052 | 21.12.2020 Original published format: EP 20216052 | EP20210160477 | 03.03.2021 Original published format: EP 21160477 | EP20210162030 | 11.03.2021 Original published format: EP 21162030 | [2023/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021245130 | Date: | 09.12.2021 | Language: | EN | [2021/49] | Type: | A1 Application with search report | No.: | EP4161956 | Date: | 12.04.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.12.2021 takes the place of the publication of the European patent application. | [2023/15] | Search report(s) | International search report - published on: | EP | 09.12.2021 | Classification | IPC: | C07K14/55, A61K38/20, A61P35/00, C12N15/85 | [2023/15] | CPC: |
C07K14/55 (EP,IL,KR,US);
A61K38/2013 (EP,IL);
A61K39/3955 (EP,IL,KR);
A61K47/542 (US);
A61K47/60 (EP,IL,KR,US);
A61P35/00 (EP,IL,KR,US);
C07K16/2818 (EP,IL);
C07K17/08 (KR);
A61K2300/00 (IL);
A61K38/00 (KR)
(-)
| C-Set: |
A61K39/3955, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/15] | Validation states | MA | 14.12.2022 | TN | 14.12.2022 | Title | German: | IL-2-SEQUENZEN UND VERWENDUNGEN DAVON | [2023/15] | English: | IL-2 SEQUENCES AND USES THEREOF | [2023/15] | French: | SÉQUENCES D'IL-2 ET LEURS UTILISATIONS | [2023/15] | Entry into regional phase | 14.12.2022 | National basic fee paid | 14.12.2022 | Designation fee(s) paid | 14.12.2022 | Examination fee paid | Examination procedure | 14.12.2022 | Examination requested [2023/15] | 14.12.2022 | Date on which the examining division has become responsible | 18.07.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.06.2023 | Renewal fee patent year 03 | 31.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2005086798 (CHIRON CORP [US], et al) [Y] 1-43 * Human mature interleukin-2 mutein K35T/C125A * * page 59, paragraph 1 * * page 48, paragraph l * * K35 mutants; page 81 - page 82, line 3 * * claim 8 * * sequence 124 *; | [Y]WO2014028748 (IRM LLC [US], et al) [Y] 1-43 * sequence 104 *; | [A]WO2018091003 (CT INMUNOLOGIA MOLECULAR [CU]) [A] 1-43 * sequences 4-6 *; | [XI]WO2019131964 (KYOWA HAKKO KIRIN CO LTD [JP]) [X] 1-14 * mutant R38C; page 115; table 2 * * sequence 1 * * claim 29 * [I] 15-43; | [A]WO2020020783 (BIONTECH RNA PHARMACEUTICALS GMBH [DE], et al) [A] 1-43 * sequences 2, 3 *; | [A]WO2020057646 (INNOVENT BIOLOGICS SUZHOU CO LTD [CN]) [A] 1-43 * claim 17 *; | [XI]CN111018961 (BEIJING LETOLABORATORIES CO LTD) [X] 1-4,6,8-14 * sequences 34, 37 * [I] 5,7,15-43; | [XPI]WO2020254607 (ASCENDIS PHARMA ONCOLOGY DIV A/S [DK]) [XP] 1-14 * sequence 3 *[I] 15-43; | [XI] - "Human mature IL-2 protein mutant R38C.", Geneseq, (20190822), Database accession no. BGM81672, URL: EBI, XP002800682 [X] 1,3,4,6 * sequence . * [I] 2,5,7-43 | by applicant | WO02089789 | WO2005027978 | EP1536334 | WO2006069246 | WO2008034122 | WO2008155134 | WO2009009712 | WO2009095479 | US7585837 | WO2009133137 | WO2009143412 | WO2010091122 | WO2011012715 | WO2011018611 | WO2011018612 | WO2011018613 | WO2011082368 | WO2011144756 | WO2012002047 | US2012035101 | WO2013024048 | WO2013036847 | WO2013036857 | US8618124 | WO2014056926 | WO2014060512 | US8754190 | US8946405 | WO2016020373 | WO2018009916 | WO2018112108 | WO2018175788 | WO2020141221 | WO2020206358 | - JONES et al., J. Am. Chem. Soc., (20120000), vol. 134, no. 3, pages 1847 - 1852 | - Clin Cancer Res, (20200000), vol. 26, pages 4442 - 7 |